Canton Strategic Holdings CEO Mark Wendland Joins Canton Foundation Board, Tharimmune Reports Clinical-Stage Biotechnology Advancements.
ByAinvest
Tuesday, Mar 3, 2026 3:11 pm ET1min read
CNTN--
Canton Strategic Holdings, Inc. chairman and CEO Mark Wendland has been elected to the Canton Foundation board. Tharimmune, Inc. is a clinical-stage biotech company developing therapeutic candidates for inflammatory and immunologic conditions. They have a Phase I clinical trial for TH104, a transmucosal film product, and preclinical development for two bispecific candidates and a Picobody candidate.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet